EGFR and lung adenocarcinoma: Therefore, existing guidelines recommend genetic testing for lung adenocarcinoma patients before treatment, such as EGFR mutations and anaplastic lymphoma kinase (ALK) fusion mutations (Zhu et al., 2008; Shan et al., 2015; Khan et al., 2018; Kang J. et al., 2020).